Skip to main content

Breast cancer

Breast cancer

03-09-2018 | Breast cancer | News | Article

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.

31-08-2018 | Breast cancer | News | Article

In other news: Breast cancer treatment effects

The focus this month is on early and late treatment effects in patients with breast cancer, including effects on endometrial cancer risk, cardiotoxicity, and skin toxicity.

28-08-2018 | Breast cancer | News | Article

Adding pertuzumab to trastuzumab effective for HER2-positive breast cancer

Adding pertuzumab to trastuzumab plus an aromatase inhibitor may be effective for patients with human HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer, a phase II trial suggests.

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

20-08-2018 | Breast cancer | News | Article

Adjuvant radiotherapy may improve DCIS outcomes

Canadian researchers have found that the use of radiotherapy after surgery for ductal carcinoma in situ leads to an improvement in breast cancer-specific survival, possibly due to its systemic effects.

10-08-2018 | Oncology | News | Article

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

03-08-2018 | Breast cancer | News | Article

CTCs predict late recurrence of HR-positive breast cancer

The presence of circulating tumour cells 5 years after the treatment of high-risk, hormone receptor-positive breast cancer is prognostic for late disease recurrence, research demonstrates.

01-08-2018 | Breast cancer | News | Article

Magnetic device helps guide breast cancer SLN biopsy

More on this US FDA decision here

30-07-2018 | Breast cancer | News | Article

TGFB1 gene key determinant of breast fibrosis risk

Carriers of the C−509T allele in the transforming growth factor ß 1 gene have a significantly increased risk for late breast fibrosis following breast-conserving surgery and whole-breast irradiation for stage 0 to IIA breast cancer, researchers report.

26-07-2018 | Breast cancer | Main feed | News

Ribociclib indication expanded to pre-, perimenopausal patients

Read more about this FDA update here

25-07-2018 | Oncology | News | Article

Assisted reproduction linked to increased breast and ovarian cancer risk

Women who undergo assisted reproduction may be at increased risk for in situ breast cancer, and invasive and borderline ovarian tumors, show results of a large, population-based study.

10-07-2018 | Breast cancer | News | Article

Acupuncture benefits unclear for aromatase inhibitor–related arthralgia

Acupuncture may provide modest reductions in aromatase inhibitor-related joint pain in postmenopausal women with early-stage breast cancer, results of a multicenter study suggest.

27-06-2018 | Breast cancer | News | Article

Higher BMI linked to reduced premenopausal breast cancer risk

Increased adiposity is associated with a decreased risk for developing breast cancer before menopause, confirms a pooled analysis published in JAMA Oncology.

25-06-2018 | Oncology | Main feed | News

Biosimilar trastuzumab receives EMA support

Read more on this positive opinion here

22-06-2018 | Breast cancer | News | Article

Mixed results for denosumab for the prevention of breast cancer recurrence

Two opposing sets of phase III results regarding the effect of denosumab on the recurrence of hormone receptor-positive nonmetastatic breast cancer have been presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

05-06-2018 | Breast cancer | News | Article

Ovarian suppression enhances outcome in premenopausal breast cancer

Adding ovarian suppression to tamoxifen significantly improves disease-free survival over tamoxifen alone in premenopausal women with hormone receptor-positive breast cancer, the latest data from the SOFT and TEXT trials show.

04-06-2018 | Breast cancer | News | Article

Gene assay could help women with early breast cancer avoid chemotherapy

Women with hormone receptor-positive, HER2-negative, axillary node-negative breast cancer who have a midrange score on the 21-tumor gene assay may be spared adjuvant chemotherapy, phase III study data show.

02-06-2018 | Breast cancer | News | Article

Shorter trastuzumab treatment feasible for HER2-positive early breast cancer

Reducing adjuvant treatment with trastuzumab from the current standard of 12 months to 6 months does not have a negative impact on disease-free survival in women with HER2-positive early breast cancer, PERSEPHONE trial data show.

31-05-2018 | Breast cancer | News | Article

Ribociclib addition boosts endocrine therapy in premenopausal women with advanced breast cancer

The addition of the cyclin-dependent kinase 4 and 6 inhibitor ribociclib to either oral tamoxifen or a nonsteroidal aromatase inhibitor improves progression-free survival in premenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer, according to findings from the phase III MONALEESA-7 study.

11-05-2018 | Breast cancer | News | Article

Germline BRCA status may influence advanced TNBC chemotherapy choice

Testing for BRCA1 and BRCA2 mutations could inform the choice of chemotherapeutic agent in women with advanced triple-negative breast cancer, suggest the results of the TNT trial.

Image Credits